Oxytocin Modulates Nociception as an Agonist of Pain-Sensing TRPV1 by Nersesyan, Yelena et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.celrep.2017.10.063
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Nersesyan, Y., Demirkhanyan, L., Cabezas-Bratesco, D., Oakes, V., Kusuda, R., Dawson, T., ... Zakharian, E.
(2017). Oxytocin Modulates Nociception as an Agonist of Pain-Sensing TRPV1. Cell reports, 21(6), 1681-1691.
DOI: 10.1016/j.celrep.2017.10.063
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 15. Dec. 2017
Article
Oxytocin Modulates Nociception as an Agonist of
Pain-Sensing TRPV1
Graphical Abstract
Highlights
d TRPV1 acts as an ionotropic oxytocin receptor in cells
d Oxytocin potentiates TRPV1 in cells and lipid bilayers
d Oxytocin interacts with TRPV1 at the extracellular pore loop
region
d Oxytocin attenuates capsaicin-induced nociception via
TRPV1 desensitization
Authors
Yelena Nersesyan, Lusine Demirkhanyan,
Deny Cabezas-Bratesco, ..., Carmen
Domene, Sebastian Brauchi, Eleonora
Zakharian
Correspondence
zakharel@uic.edu
In Brief
Oxytocin is known to suppress painful
stimuli of inflammatory origin. Nersesyan
et al. now find that oxytocin attenuates
pain via the pain-sensing receptor
TRPV1.
Nersesyan et al., 2017, Cell Reports 21, 1681–1691
November 7, 2017 ª 2017 The Authors.
https://doi.org/10.1016/j.celrep.2017.10.063
Cell Reports
Article
Oxytocin Modulates Nociception
as an Agonist of Pain-Sensing TRPV1
Yelena Nersesyan,1 Lusine Demirkhanyan,1 Deny Cabezas-Bratesco,2 Victoria Oakes,3 Ricardo Kusuda,4,5
Tyler Dawson,1 Xiaohui Sun,1,6 Chike Cao,7 Alejandro Martin Cohen,8 Bharath Chelluboina,1 Krishna Kumar Veeravalli,1
Katharina Zimmermann,4 Carmen Domene,3,9 Sebastian Brauchi,2 and Eleonora Zakharian1,10,*
1Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine, 1 Illini Drive, Peoria, IL 61605, USA
2Instituto de Fisiologia, Facultad de Medicina, Universidad Austral de Chile, and Millennium Nucleus of Ion Channels-Associated Diseases
(MiNICAD), Valdivia 5110566, Chile
3Department of Chemistry, King’s College London, Britannia House, 7 Trinity Street, London, SE1 1DB, UK
4Department of Anesthesia, Friedrich-Alexander University Erlangen-N€urnberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
5Department of Pharmacology, Ribeir~ao Preto Medical School, University of S~ao Paulo, Av. Bandeirantes 3900, 14049-900 Ribeir~ao Preto,
Brazil
6College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China
7Ion Channel Research Unit, Duke University Medical Center, Durham, NC 27710, USA
8Department of Biochemistry andMolecular Biology, Faculty of Medicine, Dalhousie University, 5850 College Street, P.O. Box 15000, Halifax,
NS B3H 4R2, Canada
9Chemistry Research Laboratory, Mansfield Road, University of Oxford, Oxford, OX1 3TA, UK
10Lead Contact
*Correspondence: zakharel@uic.edu
https://doi.org/10.1016/j.celrep.2017.10.063
SUMMARY
Oxytocin is a hormone with various actions.
Oxytocin-containing parvocellular neurons project
to the brainstem and spinal cord. Oxytocin release
from these neurons suppresses nociception of in-
flammatory pain, the molecular mechanism of which
remains unclear. Here, we report that the noxious
stimulus receptor TRPV1 is an ionotropic oxytocin
receptor. Oxytocin elicits TRPV1 activity in native
and heterologous expression systems, regardless
of the presence of the classical oxytocin receptor.
In TRPV1 knockout mice, DRG neurons exhibit
reduced oxytocin sensitivity relative to controls,
and oxytocin injections significantly attenuate
capsaicin-induced nociception in in vivo experi-
ments. Furthermore, oxytocin potentiates TRPV1 in
planar lipid bilayers, supporting a direct agonistic
action. Molecular modeling and simulation experi-
ments provide insight into oxytocin-TRPV1 interac-
tions, which resemble DkTx. Together, our findings
suggest the existence of endogenous regulatory
pathways that modulate nociception via direct action
of oxytocin on TRPV1, implying its analgesic effect
via channel desensitization.
INTRODUCTION
Oxytocin is a versatile hormone with various physiological ac-
tions. The wide range of oxytocin-elicited effects include stimu-
lation of uterine smooth muscle contraction to facilitate labor,
induction of lactation, and expression of complex social and
bonding behaviors related to reproduction and care for offspring
(Carter, 2014). Oxytocin is produced in the brain in the hypotha-
lamic paraventricular (PVN), supraoptic (SON), and intermediate
accessory nuclei (Sawchenko and Swanson, 1983). Magnocellu-
lar neurons release oxytocin into the bloodstream (Scharrer and
Scharrer, 1940) and also innervate various regions of the brain,
including the nucleus accumbens (Ross et al., 2009) and the
central nucleus of the amygdala (Knobloch et al., 2012). The
brainstem and various regions of the spinal cord (Swanson and
Sawchenko, 1983) are innervated by oxytocin-containing parvo-
cellular neurons, and the secreted neuropeptidemodulates noci-
ception via targeting C-type fibers in the dorsal root ganglion
(DRG) (Juif and Poisbeau, 2013).
Many activities of oxytocin are accomplished through the ca-
nonical oxytocin receptor (OXTR), a G-protein-coupled receptor
that is present in neural tissues, uterus, and breast (Gimpl and
Fahrenholz, 2001). However, not all oxytocin-provoked actions
have been linked to its cognate receptor. For example, oxytocin
is present at distinctly high levels in brain regions that lack OXTR
(Gimpl and Fahrenholz, 2001). Among oxytocin actions is
the regulation of Ca2+ fluxes. These responses can involve (i)
OXTR-mediated signaling via Gaq/11 that stimulates release of
Ca2+ from internal stores and (ii) the influx of extracellular Ca2+.
The latter mechanism is dependent upon the extracellular Ca2+
concentrations, which suggested the participation of voltage-
gated or ligand-coupled channels (Sanborn et al., 1998).
Here, we aimed to identify the receptor responsible for an ion-
otropic oxytocin effect. Our data indicate that oxytocin directly
targets the pain receptor, TRPV1 (transient receptor potential
vanilloid 1), a non-selective Ca2+-permeable cation channel.
TRPV1 is expressed in afferent somatosensory neurons and
along the spinal cord. The original discovery of the TRPV1 chan-
nel as a heat and capsaicin receptor validated the existence of
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nociceptive neural circuitry that mitigates awareness of noxious
stimulus exposure (Caterina et al., 1997; Julius, 2013).
In this work, using native and heterologous expression sys-
tems, we find that oxytocin-elicited Ca2+ responses are
mediated through TRPV1 channels. This activity is consistently
observed in TRPV1-expressing cells, regardless of the pres-
ence of OXTR. Furthermore, DRG neurons isolated from the
TRPV1-deficient mice displayed reduced oxytocin sensitivity
in comparison to the wild-type and other controls. Planar lipid
bilayer experiments confirmed that oxytocin can directly acti-
vate the TRPV1 channel. Molecular modeling indicated that,
similarly to the tarantula double knot toxin (DkTx), oxytocin
interacts with TRPV1 at the extracellular domain leading to
channel gating. Together, our results provide solid evidence
that oxytocin is a direct TRPV1 agonist. These results imply
that oxytocin-induced suppression of nociception might be
achieved directly through potentiation of the pain receptor
TRPV1, causing analgesia upon the desensitization of the
channel.
RESULTS
Oxytocin Elicits Ca2+ Influx through TRPV1 Channels
To assess the mechanism of oxytocin-induced anti-nociception,
we tested whether it exerts any action on pain-sensing TRPV1.
To test the effects of oxytocin on TRPV1 channels, initial exper-
iments used a heterologous expression system, HEK293 cells, to
stably express the channel. Oxytocin concentrations used were
in the low micromolar range, which matches some physiological
conditions. In the neurosecretory granules of the posterior pitu-
itary, oxytocin is present at high concentrations (>100 mM) and
is complexed to its carrier protein neurophysin (Gimpl and Fah-
renholz, 2001; Ludwig and Leng, 2006). Upon secretion,
oxytocin concentrations can range from tens to hundreds of
micromolar (Gimpl and Fahrenholz, 2001; Ludwig and Leng,
2006). In contrast, in cerebrospinal fluid, oxytocin is present in
low picomolar concentrations, while plasma oxytocin can reach
hundreds of picomolar (Kendrick et al., 1991; Winslow et al.,
2003).
Under these experimental conditions, oxytocin induced rapid
Ca2+ influx in cells stably expressing TRPV1 (Figures 1A and
1B), albeit modest in comparison to capsaicin. This effect was
not observed in HEK293 cells, used as a control (Figures 1B
and 1E). The observed TRPV1 responses displayed a rapid
desensitization, which was noticeable during the individual and
sequential oxytocin applications (Figure 1B). Co-application of
capsaicin with oxytocin elicited a stronger Ca2+ response, indi-
cating a cumulative effect of both compounds (Figures 1A
and 1B). However, the co-application also exhibited a more
rapid ‘‘run-down’’ in comparison to the control (Figures 1A and
1B). Importantly, the oxytocin-evoked activity was abolished
(1) with the pre-application of TRPV1 antagonist capsazepine
or (2) upon introduction of TRPV1-specific small interfering
RNA (siRNA) (Figures 1C, 1D, and S1). The Ca2+ imaging per-
formed on the HEK293 cells is summarized in Figure 1F.
Interesting, pre-activation of TRPV1 using capsaicin provoked
stronger responses to oxytocin (Figure S2). Under these experi-
mental conditions, oxytocin elicited TRPV1 responses beginning
at low picomolar concentrations (Figure S2). Similar channel
behavior was observed when oxytocin was applied after potenti-
ating TRPV1 with a low-pH pulse (pH 4.5 or 5.5; data not shown).
These results indicated that oxytocin potency to TRPV1 in-
creases when the channel is present in its active/open state. It
is tempting to speculate that these conditions are physiologically
relevant, reflecting increased oxytocin affinity to the channel
following TRPV1 potentiation by inflammatory stimuli.
To determine whether oxytocin-evoked Ca2+ responses are
mediated through the OXTR or vasopressin 1a receptors, we
tested these responses using G-protein-coupled receptor inhib-
itors. Cells treated with the PLC inhibitor U73122, its negative
control U73343 (following the protocol described previously
[Horowitz et al., 2005; Thyagarajan et al., 2009]), or the oxytocin
receptor (OXTR) inhibitor atosiban displayed no differences in
the oxytocin-induced responses (Figure S3).
Next, we tested TRPV1 responses using neuronal F-11 cells.
Transiently expressing TRPV1 F-11 cells promptly responded
to oxytocin (Figure 1). Unlike HEK293, TRPV1-F-11 cells demon-
strated more sustained activity and less desensitization (Figures
1G and 1H). Since the neuronal F-11 cells could also endoge-
nously express the canonical oxytocin receptor, we again tested
whether or not OXTRmediates the oxytocin-elicited Ca2+ signals
usingOXTR-specific siRNA.Nodifferenceoccurred in themagni-
tude or kinetics of oxytocin-induced responses (Figures 1G, 1H,
and S1), whereas F-11 cells transfected with control pcDNA vec-
tor were essentially unresponsive to all the stimuli (Figure 1I). The
summary of Ca2+ influx in F-11 cells is presented in Figure 1J.
We next examined oxytocin-evoked activity using DRG neu-
rons isolated from the wild-type (WT) and TRPV1 knockout
(TRPV1-KO, referred to as TRPV1/) mice (Figures 2A–2G). In
the majority of experiments, DRG neurons that were sensitive
to oxytocin were also sensitized by capsaicin. A few exceptions
were noted when the initial oxytocin-elicited responses were of
higher magnitude and were further desensitized to subsequent
applications of capsaicin or oxytocin (Figure 2A). DRG neurons
transiently expressing TRPV1 channels were sensitive to both
agonists (Figure 2B).
On average, we found no essential differences between gen-
ders. In WT female mice, oxytocin-sensitive DRGs comprised
22%, and male neurons comprised 26% (Figure 2G). In
contrast, only a few DRG neurons isolated from TRPV1-KO ani-
mals exhibited oxytocin sensitivity, comprising 5% responsive
neurons obtained from female mice and 2.2% from the males
(Figures 2C, 2D, and 2G). We hypothesized that these residual
Ca2+ signals weremediated through the other oxytocin receptors
present in DRG neurons, including OXTR, vasopressin 1a recep-
tors (V1aR), or someother receptors.Notably, these residual Ca2+
responses were kinetically slower compared to the WT mice,
which could reflect G-protein-mediated Ca2+ release from intra-
cellular stores (Figures 2A and 2C). Rescuing TRPV1 expression
in TRPV1-KODRGneurons by transiently expressing the channel
recovered their responses to both agonists (Figure 2E).
Alternatively, we tested whether other pain receptors such as
TRPA1 or TRPM8 are implicated in oxytocin-elicited activity.
However, DRG neurons from TRPA1-KO and TRPM8-KO mice
displayed similar sensitivity to oxytocin as those obtained from
the WT (Figure S4).
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Together, these results suggest that the DRG sensitivity to
oxytocin is, in large part, mediated through TRPV1 channels.
Oxytocin Evokes TRPV1 Channel Activation in
Whole-Cell Patch Clamp
Next, we assessed the effect of oxytocin on TRPV1 activity using
an electrophysiological approach. We found that oxytocin appli-
cation elicited current potentiation in whole-cell patch-clamp re-
cordings performed on HEK293 cells expressing TRPV1 (Figures
3A–3D). The channel current showed an outward rectification
similar to that of capsaicin-evoked currents. However, the
maximal response against oxytocin (10 mM) was modest
compared to that of capsaicin (1 mM) (Figure 3A). The conduc-
tance versus voltage relation was similar under both conditions
(conductance/voltage [GV] curves), suggesting that differences
in the current density are associated with differences in the
desensitization induced by these agonists. In fact, oxytocin
strongly desensitized the channel, while the observed desensiti-
zation for capsaicin was only partial (Figure 3B). Desensitization
observed in the context of the intact cells impeded our ability to
obtain the full dose-response curve, as concentrations over
30 mM rapidly inactivated the elicited current (Figure 3D).
Oxytocin Directly Activates TRPV1 in Planar Lipid
Bilayers
The use of cellular systems to decipher direct agonistic actions
of hormones can be complicated by the presence of various
signaling pathways that give rise to intermediate effects. Thus,
Figure 1. Oxytocin Evokes TRPV1 Activity
in HEK293 Cells Stably Expressing the
Channel
(A) Control experiment with 10 mM capsaicin-
induced TRPV1 activation (n exp. = 6; n cells = 81).
(B) Subsequent applications of 1 mM and 10 mM of
oxytocin, followed by 10 mM capsaicin, elicited
transient Ca2+ responses with oxytocin but a
cumulative effect in the presence of both com-
pounds (n exp. = 9; n cells = 96).
(C) Capsazepine significantly inhibited both the
oxytocin- and oxytocin/capsaicin-induced re-
sponses (n exp. = 6; n cells = 84); p values in com-
parison to those of the control in (B) are the
following: 1 mM oxytocin, p = 1.6E7; 10 mM
oxytocin, p = 9.3E7; 10 mM oxytocin/capsaicin,
p = 4.25E7).
(D) Co-expression of TRPV1-specific siRNA
(0.75 mg) and GFP (0.25 mg) significantly inhibited
all the responses (n exp. = 6; n cells = 66); p values in
comparison to those of the control in (B) are the
following: 1 mM oxytocin, p = 1.24E4; 10 mM
oxytocin, p = 3.58E4; 10 mM oxytocin/capsaicin,
p = 8.19E4).
(E) Control HEK293-cell non-expressing TRPV1
channels show no responses to any of the
agonists (n exp. = 4; n cells = 100); p values in
comparison to those of the control in (B) are the
following: 1 mM oxytocin, p = 1.04E11; 10 mM
oxytocin, p = 1.16E9; 10 mM oxytocin/capsaicin,
p = 1.88E13).
(F) The summary presents the means under all the
conditions.
Oxytocin elicits TRPV1 responses in F-11 neuronal
cells transiently expressing the channel.
(G) Oxytocin- and capsaicin-induced responses
on F-11 cells with transiently expressed TRPV1
(0.5 mg) and GFP (0.15 mg) (n exp. = 6; n cells = 71).
(H) Oxytocin- and capsaicin-induced responses
on F-11 cells with transiently expressed TRPV1
(0.5 mg), GFP (0.15 mg), and OXTR siRNA (0.4 mg)
(n exp. = 6; n cells = 60).
(I) Oxytocin- and capsaicin-induced responses on
F-11 cells with transiently expressed empty
pcDNA vector (0.5 mg) andGFP (0.15 mg) (n exp. = 6;
n cells = 48); p values in comparison to those of
TRPV1/GFP-expressing cells are the following: 1 mM oxytocin, p = 0.009; 10 mM oxytocin, p = 2.1E6; 10 mM oxytocin/capsaicin, p = 2.5E9).
(J) The summary presents the means of Ca2+ responses obtained under all the conditions.
All error bars represent ±SEM. *p < 0.05, **p < 0.01, ***p <0.001, and ****p < 0.0001.
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to validate direct actions of oxytocin on TRPV1, we used planar
lipid bilayers to characterize oxytocin-induced channel activity.
For these experiments, the TRPV1 protein was purified and
incorporated into bilayers as described previously (Lukacs
et al., 2013; Sun and Zakharian, 2015). Protein purity was
validated using liquid chromatography-mass spectrometry
(LC-MS/MS). Distinct TRPV1 peptides were identified at high
abundance (Figure S5; Table S1). After incorporating TRPV1 in
the bilayers, we found that oxytocin activates the channel
directly, similar to the other known agonists, heat (Sun and Za-
kharian, 2015) and capsaicin (Lukacs et al., 2013). Likewise,
TRPV1 opening required the presence of phosphatidylinositol-
4,5-bisphosphate (PIP2) (Figures 4 and S6).
Oxytocin-induced TRPV1 opening demonstrated distinct cur-
rent rectification and profound voltage dependence. These fea-
tures were evident in the single-channel conductance and the
open probability (Figures 4A–4D). The channel exhibited the
outward current with the mean slope conductance of 81 pS,
while the inward current was 20 pS (Figures 4A and 4C). In
addition, oxytocin-evoked TRPV1 openings showed strong
voltage dependence, with marked low open probability obtained
at negative voltages and an exponentially increasing open
Figure 2. Oxytocin Sensitivity Is Diminished in DRG Neurons Isolated from TRPV1-Deficient Mice
(A) Oxytocin- and capsaicin-elicited Ca2+ responses in DRG neurons obtained from the WT mice (number of experiments [nexp.] = 33).
(B) Oxytocin- and capsaicin-elicited Ca2+ responses in the WT DRG neurons transiently expressing TRPV1 (3 mg) together with GFP (0.5 mg), (nexp. = 6).
(C and D) show oxytocin and capsaicin sensitivity of DRG neurons obtained from TRPV1-KO (C) female (nexp. = 21) and (D) male (nexp. = 21) mice, respectively.
(E) Oxytocin- and capsaicin-induced responses obtained from the TRPV1-KO (/) DRG neurons transiently expressing TRPV1 (3 mg) along with GFP (0.5 mg),
(nexp. = 6).
(F) Summary of oxytocin- and capsaicin-induced responses obtained from WT and WT with transiently expressed TRPV1 channels.
(G) Pie graphs present distribution of the oxytocin-sensitive and oxytocin-insensitive DRG neurons isolated from the WT female (ncells = 284), WT male
(ncells = 482), TRPV1-KO female (ncells = 318), and TRPV1-KO male (ncells = 318) mice.
All error bars represent ±SEM.
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probability at positive potentials (Figures 4A, 4B, and 4D). In
planar lipid bilayers, oxytocin activated TRPV1 with a half-
maximal effective concentration (EC50) of 0.32 mM (Figure 4E).
The comparison of oxytocin-evoked TRPV1 activity to that of
capsaicin demonstrated that both conductance values of capsa-
icin-induced inward and outward currents were greater than that
of oxytocin by about 20 and 22 pS, respectively (Figure 4F). The
open probability of the channel was similar at negative voltages
with both agonists, whereas the open probability was greater at
positive voltages for capsaicin-evokedTRPV1 activity (Figure 4G).
In summary, the planar lipid bilayer experiments confirmed
that oxytocin is a direct TRPV1 agonist, and this activity can
occur independent of any other intermediate signaling pathway.
Identification of an Oxytocin-Binding Site
To investigate the interaction between oxytocin and the TRPV1
ion channel at the atomic level, computational studies were per-
formed on the TRPV1 homotetramer. To that end, oxytocin
molecules were docked onto the pore loop region of structures
representing the open and closed states of the channel, and
MD simulations of the resulting complexes were performed
(see Experimental Procedures). Negligible binding to the closed
state was observed.
In contrast, theopenstate (denoted simulationPep1) interacted
with a single oxytocinmolecule via its extracellular pore loop. The
interaction persisted for approximately 200 ns, with the most
prevalent binding pose (clustered using a 3-A˚ root-mean-square
deviation [RMSD] criterion) observed for 80 ns. In a further simu-
lation (denoted simulation Pep2) with four oxytocin molecules
initiated from this binding pose, interaction with a single oxytocin
peptide persisted for the duration of the 200-ns trajectory, with a
stable binding pose observed for 150 ns (Figures 5A–5E).
The identified binding site lies on the external surface of the
transmembrane domain, in the interfacial region between two
Figure 3. Oxytocin Potentiates TRPV1 Currents in Whole-Cell Patch-Clamp Recordings
(A) Current-voltage (I-V) relations obtained from voltage ramps from 140 mV to +140 mV in the presence of vehicle (black), 10 mM oxytocin (blue) or 1 mM
capsaicin (red). EM, membrane electric potential.
(B) Top: time course of representative 10 mM oxytocin and 1 mM capsaicin responses. Bottom: the overlay of normalized responses showing differences in the
desensitization kinetics.
(C) Left: G-V curves were obtained by plotting peak tail currents at100 mV in response to voltage-activated steady-state currents from160 mV to +160 mV in
20-mV increments: voltage for half-maximal activation of a channel (Vm) values for control, 121.66 ± 14.29 (n = 12); for oxytocin, 64.22 ± 8.96 (n = 12); and for
capsaicin, 76.25 ± 21.03 (n = 4); charge z for control, 0.85 ± 0.07 (n = 12); for oxytocin, 0.75 ± 0.06 (n = 12); and for capsaicin, 0.67 ± 0.108 (n = 4). Right:
representative traces obtained in transfected cells subjected to voltage steps in control conditions (black) or in the presence of 10 mM oxytocin (blue) or 1 mM
capsaicin (red).
(D) Dose-response curve fitted to concentrations <30 mM. EC50 = 7.74 ± 8.5; h = 1.5 ± 0.6.
All error bars represent ±SEM.
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adjacent subunits. The predicted binding site is illustrated in Fig-
ure 5E. The extension of this computational analysis and further
discussion of the influence on the TRPV1 activation state are
presented in the Supplemental Information (see also Figure S7).
Oxytocin Interaction with TRPV1: Similarity with Other
Agonists
Next, we compared theTRPV1activation of oxytocin to that of the
tarantula toxinDkTx. The latter hasbeenstudiedextensively using
both experimental and computational approaches (Bae et al.,
2016; Bohlen et al., 2010). Mutations I599A, F649A, A657P, and
F659A inhibit channel activation by DkTx, whereas V595A and
T695A attenuate channel activation to a lesser extent (Bohlen
et al., 2010). Conversely, Y631A enhanced activation by DkTx
(Bohlen et al., 2010). The atomic model of TRPV1 in complex
with DkTx, determined by Bae et al., advocated that some of
the residues, Y631, F649, A657, and T650, were in direct contact
with the toxin (Bae et al., 2016). Remarkably, such interactions are
replicated in the model of oxytocin-bound TRPV1, thus suggest-
ing that oxytocinmay activate TRPV1 via a pathway similar to that
of DkTx. Furthermore, our simulations revealed direct engage-
ment between oxytocin and A649 in both apo and holo TRPV1
structures, identifying an explicit pathway by which oxytocin
couldmodulate the behavior of this region and potentiate TRPV1.
To validate the TRPV1-oxytocin-binding site derived from
computational analysis, we altered the most promising target
Figure 4. Oxytocin Directly Activates TRPV1 in Planar Lipid Bilayers in the Presence of PIP2
(A) Representative single-channel current traces of oxytocin-induced (0.5 mM) TRPV1 obtained in the presence of PIP2 (5 mM); voltages are indicated on the left.
(B) Representative ramp recording obtained at 150 to +150 mV.
(C and D) Graphs demonstrate current voltage relationship (C) and voltage dependence (D) of oxytocin-induced TRPV1; n = 12.
(E) Dose response of oxytocin-TRPV1 activation; EC50 = 0.316 mM ± 0.02 mM.
(F) Current voltage relationship of oxytocin- and capsaicin-induced TRPV1 channels.
(G) Capsaicin induces higher open probability of TRPV1 outward channel activity, as indicated by open probability differences of oxytocin-elicited (2 mM) and
capsaicin-elicited (2 mM) openings at 60 and +60 mV.
All error bars represent ±SEM.
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residues by mutagenesis and tested their function. Patch-clamp
recordings showed that L635A and F649A TRPV1 mutants
completely lose their sensitivity to oxytocin. Surprisingly, they
were also insensitive to capsaicin (Figures 6A and 6B) but
displayed potentiation by heat (Figures 6C and 6D). Conversely,
D646A mutation did not alter the sensitivity of TRPV1 to oxytocin
(Figure 6A). Together, these experiments are consistent with
the hypothesis that oxytocin interacts with TRPV1 via L635
and F649.
Oxytocin ReducesCapsaicin-InducedAversiveBehavior
in Mice
In conclusion, our findings suggest that oxytocin suppresses
nociception via activation and desensitization of the polymodal
TRPV1 channels in nociceptors. To test this hypothesis, we
performed in vivo experiments to quantify nocifensive behavior
in mice subsequent to oxytocin and capsaicin application.
Oxytocin alone did not provoke any noticeable aversive
Figure 5. Modeling and Molecular Dynamics Stimulations Display Oxytocin-TRPV1-Interacting Site
(A–E) Contact map displaying the number of interacting atom pairs (NP) between TRPV1 and oxytocin in simulation Pep1 (A) and Pep2 (B), averaged over the
simulation length, using a 4-A˚ cutoff. The prominent interactions (defined as NP > 15) are summarized in (C). The occurrence of hydrogen bonds is displayed in (D).
In (E), a new cartoon representation of the TRPV1 system, in complex with oxytocin is illustrated; oxytocin and interacting TRPV1 residues are displayed in licorice
representation.
Figure 6. L635A and F649A Mutants Lose
Sensitivity to Oxytocin
Patch-clamp recording show the current obtained
from the wild-type TRPV1 and mutants. (A) dem-
onstrates representative whole-cell currents re-
corded by using gap-free protocol with a holding
potential at 70 mV. Traces are shown in current
densities (picoamperes per picofarad; pA/pF). (B)
presents the summary of the relative to control
current of TRPV1 wt, L635A, D646A, and F649A
constructs obtained upon application of 1 mM
capsaicin and 10 mM oxytocin, n = 5 for each
construct. (C) displays voltage ramp recordings of
heat-induced potentiation of the wild-type TRPV1
and the mutants upon exposure to 40C pulses.
The summary of the heat-induced activities is
presented in (D). *p < 0.05, **p < 0.01, ***p < 0.001.
All error bars represent ±SEM.
response in mice. However, co-applica-
tion of oxytocin with capsaicin signifi-
cantly induced analgesia over the capsa-
icin-evoked pain stimuli (Figure 7).
Together, these results support a direct
link between oxytocin and antinocicep-
tion via TRPV1 activity modulation.
DISCUSSION
Physiological Implication of
Oxytocin in Pain Modulation via
TRPV1
Oxytocin is a highly abundant neurohypo-
physial peptide. Its prevalent site of
expression is localized to themagnocellular neurons of the hypo-
thalamic paraventricular and supraoptic nuclei (see, for review,
Gimpl and Fahrenholz, 2001). Magnocellular oxytocin neurons
of these nuclei innervate the forebrain and intensely release the
hormone to the systemic circulation from the posterior pituitary
in response to a variety of stimuli. The parvocellular oxytocin
neurons further project to the brainstem and spinal cord, where
the hormone was shown to modulate inflammatory pain pro-
cessing (Eliava et al., 2016). Furthermore, this neuropeptide is
also synthesized in peripheral tissues, such as uterus, placenta,
amnion, corpus luteum, testis, and heart (Gimpl and Fahrenholz,
2001).
Physiologic roles of oxytocin range from various modalities of
neuroendocrine reflexes to the complex social and bonding be-
haviors related to reproduction and care of offspring. It is now
well established that oxytocin facilitates reproduction in all verte-
brates (Gimpl and Fahrenholz, 2001). A well-known action of the
hormone is the stimulation of milk ejection that was confirmed on
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the model of oxytocin-deficient mice. The role of oxytocin in
parturition is also established, although it involvesmore complex
regulatory mechanisms. Some evidence indicates that, from the
paraventricular nuclei of the hypothalamus, oxytocin can reach
the central amygdala, where the hormone modulates emotion-
related centers of the amygdala and brainstem (Stoop, 2012).
Many oxytocin actions have been well characterized by the func-
tion of its classical receptor OXTR, a class I G-protein-coupled
receptor that is differentially expressed in various tissues (Gimpl
and Fahrenholz, 2001). The expression of the oxytocin receptor
in the uterus and hypothalamus is strongly correlative with the
presence of sex hormones, particularly estrogens. The estrogen
receptors were shown to play the role of transcription factors of
OXTR and are required for its expression mediated by estrogen
binding (Young et al., 1998). Some oxytocin actions, however,
imply OXTR-independent mechanisms.
Among its many activities, oxytocin is known to be involved in
nociception and pain responses. These involve both peripheral
components (Juif and Poisbeau, 2013) and central components
(Gonza´lez-Herna´ndez et al., 2014; Juif et al., 2013). Importantly,
oxytocin neurons project directly into the C-type fibers of DRG
(Juif and Poisbeau, 2013). In an animal model, oxytocin release
suppresses nociception and induces analgesia by specifically
affecting inflammatory pain pathways (Eliava et al., 2016). The
oxytocin neuronal circuitry appears to occur via a dual process,
by (1) releasing oxytocin from axons onto sensory spinal cord
neurons and inhibiting their activity and (2) indirectly stimulating
oxytocin release from supraoptic neurons into the periphery (Eli-
ava et al., 2016). Thus, oxytocin modulates pain by reaching the
spinal cord through fast neuronal projections and slower periph-
eral pathways (Eliava et al., 2016). Likewise, analgesic actions of
oxytocin have been documented for migraine patients treated
with intranasal oxytocin administration (Wang et al., 2013). One
aspect of oxytocin-promoted pain regulation involves endoge-
nous analgesia (Gonza´lez-Herna´ndez et al., 2014). However, it
is still debatable as to whether this effect is mediated through
the OXTR, V1aR, or some other receptor, as themajority of these
studies have been based upon pharmacological approaches
using either OXTR or V1aR antagonists (for a review, see Gonza´-
lez-Herna´ndez et al., 2014).
Also important is the effect of oxytocin on thermoregula-
tion. Similarly to capsaicin (Kobayashi et al., 1998), periph-
eral administration of oxytocin induces strong hypothermia
(Hicks et al., 2014). Hence, in addition to analgesia, our finding
suggests a possible molecular mechanism for oxytocin-induced
hypothermia.
The results reported here suggest that several oxytocin effects
may be mediated by interaction with the TRPV1 pain receptor.
TRPV1 is a well-investigated receptor in the pain pathway. The
original discovery of TRPV1’s role in nociception inspired the
development of novel classes of analgesic drugs (Caterina
et al., 1997; Julius, 2013). Furthermore, TRPV1 serves as a mo-
lecular marker for the nociceptive neuronal circuitry that enables
sensation of noxious heat, protons, neurogenic inflammation,
and thermal hyperalgesia (Julius, 2013). Profound TRPV1
expression in C-fibers contributes to the signaling associated
with acute and chronic pain conditions and could be implicated
in various pathophysiological conditions such as arthritis,
pancreatitis, migraine headache, and others.
Indeed, the expression of TRPV1 in trigeminal afferent neurons
of dura mater suggested a plausible linkage of the channel ac-
tions to migraine (Huang et al., 2012; Shimizu et al., 2007).
More evidence for this relationship was suggested by the effect
of capsaicin on dilation of dural vessels (Akerman et al., 2003)
and induction of trigeminal ganglion neuronal activity (Iwashita
et al., 2013). However, themechanisms bywhich TRPV1 contrib-
utes to initiating or propagating the neuronal signaling related to
migraine are poorly understood (for a review, see Dussor et al.,
2014). Our discovery of oxytocin as an endogenous agonist for
the TRPV1 channel may shed more light onto the regulatory
mechanisms that underlie physiology and pathology related to
headaches and chronic migraine development.
The ability of oxytocin to modulate nociception is most likely
achieved by activation of TRPV1, followed by its marked desen-
sitization. Such mechanism is evident in nocifensive mice
behavior, where oxytocin attenuates capsaicin-evoked nocicep-
tive response (Figure 7). This is consistent with the fact that ther-
apeutic targeting of TRPV1 has been primarily advanced via
exogenous agonists that lead to prompt channel desensitization.
These treatment options are traditionally based on capsaicin-
containing remedies, such as capsaicin cream or high-concen-
tration capsaicin patches (Dussor et al., 2014). Intranasal capsa-
icin administration has also been tested in treating migraine;
similar to another TRPV1 agonist civanide, capsaicin reduced
the frequency of cluster headache attacks (Diamond et al.,
2000; Fusco et al., 2003). In contrast, attempts to identify effec-
tive and safe TRPV1 antagonists have been stymied by
numerous complications, including dysregulation of internal
body temperature. In this light, identifying the endogenous
Figure 7. Oxytocin Reduces Capsaicin-Induced Aversive Behavior
in Mice
Mouse hindpaws were intracutaneously injected under light sevoflurane
anesthesia with the vehicle (n = 3), oxytocin (4 mg per paw; n = 3), capsaicin
(1.6 mg per paw; n = 6), or a combination of capsaicin and oxytocin (4 mg per
paw; n = 6), and nocifensive behavior was quantified as the time spent licking
and flinching. Columns represent the amount of time (in seconds) animals
spent licking and flinching the injected paw during the 30-min observation
period following the injection (mean ± SEM; p value according to Student’s
t test). nd, not determined. All error bars represent ±SEM.
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mechanisms of TRPV1 potentiation and desensitization by
oxytocin along with the patterns of expression and their func-
tional relationship within the neuronal network offers a valuable
asset to pain regulation.
EXPERIMENTAL PROCEDURES
For detailed methods, see the Supplemental Information.
Cell Culture
HEK293 cells were maintained in minimal essential medium (MEM) as
previously described (Zakharian et al., 2009). F-11 cells were cultured in
DMEM/F12 medium as previously described (Zakharian et al., 2009). Mouse
DRG neurons were cultured in primary neuron basal medium (PNBM), (Lonza,
Allendale, NJ).
Whole-Cell Patch-Clamp Recordings
The whole-cell patch-clamp experiments were performed as previously
described (Yudin et al., 2011; Zakharian et al., 2009). HEK293T cells were
cotransfected with rTRPV1 and EGFP with Lipofectamine 2000 according
to the manufacturer’s protocol. Whole-cell patch-clamp recordings were per-
formed 48–72 hr post-transfection at room temperature.
Intracellular Ca2+ Measurements
Ca2+measurements were performed as previously described (Zakharian et al.,
2009).
Preparation of the TRPV1 Protein from HEK Cells
TRPV1 protein isolation was performed as previously described (Sun
and Zakharian, 2015; Zakharian et al., 2010). TRPV1 was purified by immuno-
precipitation with anti-Myc-IgG conjugated to A/G protein magnetic beads
(Pierce, Thermo Scientific, Milwaukee, WI). For the planar lipid bilayer experi-
ments, the protein was eluted with Myc-peptide (150 mg/mL).
Planar Lipid Bilayer Measurements
Planar lipid bilayer measurements and temperature studies were performed as
previously described (Sun and Zakharian, 2015; Zakharian, 2013; Zakharian
et al., 2010).
Animal Studies
Age-matched male and female wild-type and TRPV1/, TRPA/, and
TRPM8/ mice were purchased from Jackson Laboratory (Maine, USA).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.10.063.
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